source
- Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerAdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a rad…Endpoints · 14d ago↗ source
- STAT+: Celcuity’s breast cancer drug approved, its firstFDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The ReadoutSTAT · 14d ago↗ source
- Deaths from coronary artery disease have fallen, but more progress is within reachManaging risk factors is the key to further progress in reducing deaths from coronary artery disease, a new study finds.STAT · 14d ago↗ source